手性是指一个物体或分子在结构上不能与其镜像完全重合的特性。并非所有分子都具有手性，手性分子 和与它互为镜像的异构体可能存在很大的性质差异。科学家此前已知，手性分子在生物系统内广泛存 在，蛋白质、糖、DNA和RNA的基本单元，如氨基酸、单糖和核苷酸，均存在手性且通常以单一手性 存在。 研究人员认为，新发现的机制与量子化学中的"手性诱导的自旋选择性"效应一致，后者描述了具有特定 手性的分子如何与不同自旋方向的电子选择性地相互作用。这一发现意味着，生命体系中的能量与信息 传递可能比先前认为的更具选择性和可控性。质子在生物体系中的运动不仅仅是化学过程，还与量子物 理学有关。 公报说，该研究进一步印证了生命现象中蕴含量子机制的可能性，为量子物理学与生物化学的融合研究 提供了重要例证。这一耦合机制有助于开发控制细胞内信息传递等用途的新型仿生技术。研究人员也强 调，该实验是在实验室条件下在纯化的溶菌酶晶体中进行的，因此存在局限性，尚不清楚观察到的现象 如何在活细胞内的复杂环境中发挥作用。（完） 新华社耶路撒冷5月16日电（记者王卓伦 陈君清）以色列一项新研究发现，生物体系中至关重要的质 子转移过程不仅受到化学因素影响，还受 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Viewpoints - The company is positioned as a rare asset in the AI for Science sector, aiming to disrupt traditional R&D paradigms and unlock significant market potential [1][14]. - The company has achieved a revenue milestone that qualifies it as a commercial entity under Hong Kong Stock Exchange rules, with a notable reduction in net losses [8][14]. - The integration of dry and wet lab experiments creates a data barrier that strengthens the company's competitive moat [8][14]. - The company is making progress in its collaborative drug pipeline and expanding its client base in new materials and other sectors [8][14]. - Short-term growth is driven by policy incentives, while long-term growth is supported by customer retention and successful project incubation [8][14]. Summary by Sections 1. AI for Science as a Rare Asset - The company, founded in 2015, leverages quantum physics and AI to provide innovative R&D solutions across pharmaceuticals and materials science [14]. - The founding team consists of MIT-trained scientists, enhancing the company's R&D capabilities [8][14]. - The company has raised approximately $732 million from global investors, establishing itself as a leader in AI-enabled drug discovery [17][19]. 2. AI Solutions and Automation Industry - The AI solutions market is expected to grow significantly, particularly in healthcare and materials science [26][30]. - The global automation market is rapidly expanding, with laboratory automation penetration projected to increase from 3.7% in 2022 to 23.2% by 2030 [27][30]. - The convergence of data growth, labor cost increases, and technological integration is driving the growth of AI solutions and automation [34]. 3. Revenue and Profitability Forecast - The company forecasts revenues of RMB 4.26 billion, RMB 6.83 billion, and RMB 10.95 billion for 2025, 2026, and 2027, respectively, with a projected return to profitability by 2027 [1][8]. - The adjusted net loss is expected to narrow significantly over the forecast period, indicating improving financial health [1][8]. 4. Market Trends and Opportunities - The AI drug discovery market is anticipated to grow from RMB 2.76 billion in 2022 to RMB 67.7 billion by 2025, driven by advancements in technology and increased collaboration [41][42]. - The solid-state R&D services market is projected to grow at a CAGR of 27.7%, reaching $20.9 billion by 2030 [52].

在医药界有一个"双十定律"：一款创新药从启动研发到上市，平均成本超过10亿美元，研发时间超过10年，且约90%的药物会在临床试验阶段失败。 港股公司晶泰科技正通过技术的变革，重塑药物研发的生产力范式：公司以量子物理、人工智能（AI）、云计算、机器人实验等前沿技术助力生物医药、材料科学 等产业提质增效，持续培育新质生产力，助力未来产业发展。 地处香港北部和深圳中南部连接地带的河套深港科技创新合作区，是粤港澳大湾区以科技创新为主题的特色平台。在合作区的核心地带，晶泰科技的AI机器人实验 室宛如一座充满智慧与秩序的智能蜂巢，以其独有的节奏悄然有序地运作着，精密而高效。 晶泰科技董事长温书豪在接受证券时报记者采访时表示："人工智能、机器人实验等先进技术如果能在早期靶点发现、分子设计、化合物合成等阶段形成助力，将极 大缩短新药研发时间，同时降低各项成本、提高研发成功率。" 技术底座创新：量子物理、AI、机器人融合 在晶泰科技AI机器人实验室里，研发人员只需要在电脑操控台上下达指令，各司其职的机器人们便忙碌了起来：取料、运输、加料、反应、监测、测试…… 2015年创立的晶泰科技将量子物理、人工智能、机器人与大规模云计算相 ...